LEADER 01528nam 2200397 n 450 001 996388218303316 005 20221108071947.0 035 $a(CKB)1000000000636287 035 $a(EEBO)2248522528 035 $a(UnM)99848783 035 $a(EXLCZ)991000000000636287 100 $a19920117d1638 uy | 101 0 $aeng 135 $aurbn||||a|bb| 200 00$aSir Thomas Overbury his Wife. With additions of new characters, and many other witty conceits never before printed$b[electronic resource] 205 $aThe sixteenth impression. 210 $aLondon $cPrinted by Iohn Haviland, for A. Crooke, and are to be sold at the signe of the Beare in Pauls Church-yard$d1638 215 $a[320] p 300 $aOriginally published in 1614 as: A wife now a widowe. 300 $aIncludes 32 characters written by John Webster. 300 $aPartly in verse. 300 $aSignatures: A-V. 300 $aReproduction of the original in Cambridge University Library. 330 $aeebo-0021 606 $aCharacters and characteristics$vEarly works to 1800 615 0$aCharacters and characteristics 700 $aOverbury$b Thomas$cSir,$f1581-1613.$01002138 701 $aWebster$b John$f1580?-1625?$065181 801 0$bCu-RivES 801 1$bCu-RivES 801 2$bCStRLIN 801 2$bWaOLN 906 $aBOOK 912 $a996388218303316 996 $aSir Thomas Overbury his Wife. With additions of new characters, and many other witty conceits never before printed$92366579 997 $aUNISA LEADER 03292nam 22005175 450 001 9910484304603321 005 20200711110453.0 010 $a3-658-14334-7 024 7 $a10.1007/978-3-658-14334-3 035 $a(CKB)3710000000718365 035 $a(EBL)4538066 035 $a(DE-He213)978-3-658-14334-3 035 $a(MiAaPQ)EBC4538066 035 $a(EXLCZ)993710000000718365 100 $a20160602d2016 u| 0 101 0 $ager 135 $aur|n|---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAll-Age-Literatur $eDie Entdeckung einer neuen Zielgruppe und ihrer Rezeptionsmodalitäten /$fvon Maria Bertling 205 $a1st ed. 2016. 210 1$aWiesbaden :$cSpringer Fachmedien Wiesbaden :$cImprint: Springer VS,$d2016. 215 $a1 online resource (210 p.) 225 0 $aResearch 300 $aDescription based upon print version of record. 311 $a3-658-14333-9 320 $aIncludes bibliographical references. 327 $aRezeptionsmodalitäten nach Monika Suckfüll -- Empirische Untersuchung: Rezeptionsmodalitäten der Lesegruppen -- Emotionen beim Lesen -- Quantitative Literaturwissenschaft: Textanalyse. 330 $aMaria Bertling untersucht die Zielgruppe der All-Age-Leser, also Erwachsene, die Kinder- und Jugendbücher lesen. Anhand einer empirischen Untersuchung, die auf dem Konstrukt der Rezeptionsmodalitäten von Monika Suckfüll aufbaut, zeigt die Autorin, dass es eine Lesegruppe erwachsener Leser gibt, die All-Age-Literatur liest und die sich von anderen Lesegruppen abgrenzt. Außerdem stellt die Arbeit heraus, dass es einen signifikanten Zusammenhang zwischen All-Age-Literatur und einem ?emotionalen Zugang? zu Literatur gibt. Daraufhin wird die All-Age-Literatur exemplarisch mit Hilfe eines Emotionswortschatzes auf ihren Emotionsgehalt hin untersucht. Das Ergebnis: All-Age-Literatur hat eine höhere Anzahl an negativen Emotionsworten und erfüllt so alle Voraussetzungen für eine unterhaltende Lektüre. Der Inhalt Rezeptionsmodalitäten nach Monika Suckfüll Empirische Untersuchung: Rezeptionsmodalitäten der Lesegruppen Emotionen beim Lesen Quantitative Literaturwissenschaft: Textanalyse Die Zielgruppen Dozierende und Studierende der Buch-, Medien- und Literaturwissenschaft sowie der Kommunikationswissenschaft Buchhändler, Verlagsmitarbeiter und Bibliothekare Die Autorin Maria Bertling hat Buchwissenschaft, Amerikanistik und Germanistik an der Friedrich-Alexander-Universität Erlangen-Nürnberg, University College Cork und Johannes Gutenberg-Universität Mainz studiert. 606 $aCommunication 606 $aSociology 606 $aMass media 606 $aMedia Research$3https://scigraph.springernature.com/ontologies/product-market-codes/X29000 606 $aMedia Sociology$3https://scigraph.springernature.com/ontologies/product-market-codes/X22110 615 0$aCommunication. 615 0$aSociology. 615 0$aMass media. 615 14$aMedia Research. 615 24$aMedia Sociology. 676 $a300 700 $aBertling$b Maria$4aut$4http://id.loc.gov/vocabulary/relators/aut$01229500 906 $aBOOK 912 $a9910484304603321 996 $aAll-Age-Literatur$92853892 997 $aUNINA LEADER 06020nam 22007335 450 001 9910298266803321 005 20200706080048.0 010 $a3-319-17275-1 024 7 $a10.1007/978-3-319-17275-0 035 $a(CKB)3710000000434121 035 $a(EBL)2095901 035 $a(SSID)ssj0001525089 035 $a(PQKBManifestationID)11917408 035 $a(PQKBTitleCode)TC0001525089 035 $a(PQKBWorkID)11496145 035 $a(PQKB)11693335 035 $a(DE-He213)978-3-319-17275-0 035 $a(MiAaPQ)EBC2095901 035 $a(PPN)186398182 035 $a(EXLCZ)993710000000434121 100 $a20150611d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aResistance to Immunotoxins in Cancer Therapy /$fedited by Rama Shanker Verma, Benjamin Bonavida 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015. 215 $a1 online resource (259 p.) 225 1 $aResistance to Targeted Anti-Cancer Therapeutics,$x2196-5501 ;$v6 300 $aDescription based upon print version of record. 311 $a3-319-17274-3 320 $aIncludes bibliographical references and index. 327 $aPreface ; About the Editor ; Contents; Contributors; Chapter-1; Targeted Cancer Therapy: History and Development of Immunotoxins; 1.1 Introduction; 1.2 Chemotherapy; 1.3 Cancer Immunotherapy; 1.3.1 Antibodies in Cancer Therapy; 1.3.2 Tumor Antigens; 1.3.3 Antibodies for the Clinic; 1.3.4 Antibodies as Carriers; 1.4 Immunotoxins in Cancer Therapy; 1.4.1 Targeting Moiety; 1.4.2 Toxins in Cancer Immunotherapy; 1.5 Construction of an Immunotoxin; 1.6 Internalization and Cytotoxic Activity of Immunotoxins; 1.7 Immunotoxins in Clinical Study; 1.8 Conclusions; References; Chapter-2 327 $aImmunotoxins, Resistance and Cancer Stem Cells: Future Perspective2.1 Introduction; 2.2 Factors Responsible for Cancer Resistance; 2.2.1 Gene Mutations in Signalling Pathways; 2.2.2 Drug Transporters; 2.2.3 Tumor Microenvironment and Accessibility; 2.3 Resistance to Immunotoxins; 2.3.1 Dysfunctional Apoptotic Pathways; 2.3.2 ABC Transporters; 2.3.3 Lysosomal Degradation; 2.3.4 Other Factors; 2.4 Cancer Stem Cells and Resistance; 2.4.1 Drug Efflux; 2.4.2 Detoxification and Cellular Repair; 2.4.3 DNA Repair and Modification; 2.4.4 Survival Pathways; 2.4.5 Autophagy and EMT; 2.4.6 Quiescence 327 $a2.4.7 Microenvironment2.5 Strategies Used to Overcome Resistance; 2.5.1 Inhibitors of Anti-apoptotic Proteins; 2.5.2 Blocking Membrane Drug Transporters; 2.5.3 Delivery and Intracellular Trafficking; 2.5.4 Inhibition of DNA Repair and Telomerase Activity; 2.5.5 Combination Therapy; 2.5.6 Nanotechnology; 2.5.7 Other Novel Strategies; 2.6.1 Targeting Signaling Pathways in CSC's; 2.6 Targeting Cancer Stem Cells; 2.6.2 Targeting Apoptosis and Cellular Repair Mechanisms in CSC's; 2.6.3 Targeting Autophagy and Microenvironment in CSC's; 2.6.4 Targeting Membrane Transporters and CSC Surface Markers 327 $a2.7 ConclusionReferences; Chapter-3; Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins; 3.1 Introduction; 3.2 Intoxication Pathways Define Determinants for Sensitivity and/or Resistances of Tumor Cells Towards Immunotoxins; 3.3 Step 1-Access to Target Cells: Immunogenicity can be a Relevant Factor for Immunotoxin Therapy; 3.4 Step 2-Target Cell Binding: Loss or Reduction of Target Antigens Reduce Sensitivity of Tumor Cells Towards Targeted Toxins 327 $a3.5 Step 3-Entry of Toxins into Cells: Loss of Processing Enzymes and Modulation of Vesicular Compartments Reduce Toxin Activity in Cultured Cells3.6 Step 4-ADP-Ribosylation of eEF2: Reduced or Altered Expression of Diphthamide Synthesis Genes is Associated with Immunotoxin Resistances; 3.7 Step 5-Signaling and Apoptosis: Protective Factors and Pathways can Reduce Toxin Sensitivity; 3.8 Conclusions and Outlook; References; Chapter-4; Cell Signaling and Resistance to Immunotoxins; 4.1 Introduction; 4.2 Conceptual Considerations on Cellular Immunotoxin Resistance 327 $a4.2.1 Alteration of Immunotoxin Resistance via Modulation of Caspase Activation Pathways 330 $aThis volume is a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance. 410 0$aResistance to Targeted Anti-Cancer Therapeutics,$x2196-5501 ;$v6 606 $aCancer$xResearch 606 $aDrug resistance 606 $aPharmacology 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aDrug Resistance$3https://scigraph.springernature.com/ontologies/product-market-codes/B16020 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 615 0$aCancer$xResearch. 615 0$aDrug resistance. 615 0$aPharmacology. 615 14$aCancer Research. 615 24$aDrug Resistance. 615 24$aPharmacology/Toxicology. 676 $a615.373 702 $aVerma$b Rama Shanker$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aBonavida$b Benjamin$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910298266803321 996 $aResistance to Immunotoxins in Cancer Therapy$92496861 997 $aUNINA